Ocuphire Pharma, Inc. OCUP
We take great care to ensure that the data presented and summarized in this overview for Ocuphire Pharma, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding OCUP
View all-
Perceptive Advisors LLC New York, NY4.33MShares$4.24 Million0.19% of portfolio
-
Bios Capital Management, LP Fort Worth, TX3.68MShares$3.61 Million4.77% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT3.35MShares$3.28 Million0.14% of portfolio
-
Opaleye Management Inc. Boston, MA1.22MShares$1.2 Million0.29% of portfolio
-
Mink Brook Asset Management LLC West Palm Beach, FL1.2MShares$1.17 Million0.98% of portfolio
-
Vanguard Group Inc Valley Forge, PA992KShares$972,3560.0% of portfolio
-
Bleichroeder LP New York, NY737KShares$722,1050.23% of portfolio
-
Voss Capital, LLC Houston, TX541KShares$530,3350.04% of portfolio
-
Geode Capital Management, LLC Boston, MA356KShares$348,5630.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny153KShares$150,2420.0% of portfolio
Latest Institutional Activity in OCUP
Top Purchases
Top Sells
About OCUP
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances; and Phase 2b clinical trial for pharmacologically induced mydriasis, as well as that has completed Phase 2 VEGA-1 trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan.
Insider Transactions at OCUP
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 25
2025
|
Cam Gallagher |
BUY
Grant, award, or other acquisition
|
Direct |
869,565
+32.45%
|
$869,565
$1.15 P/Share
|
|
Aug 25
2025
|
Sean Ainsworth |
BUY
Grant, award, or other acquisition
|
Direct |
86,956
+25.44%
|
$86,956
$1.15 P/Share
|
|
May 05
2025
|
Foundation Fighting Blindness Retinal Degeneration Fund Director |
BUY
Conversion of derivative security
|
Direct |
6,927,419
+42.19%
|
-
|
|
Apr 30
2025
|
Cam Gallagher |
BUY
Grant, award, or other acquisition
|
Direct |
79,504
+7.79%
|
-
|
|
Apr 30
2025
|
Adrienne L Graves |
BUY
Grant, award, or other acquisition
|
Direct |
79,504
+50.0%
|
-
|
|
Apr 30
2025
|
James S J Manuso |
BUY
Grant, award, or other acquisition
|
Direct |
79,504
+23.3%
|
-
|
|
Apr 30
2025
|
Richard J Rodgers |
BUY
Grant, award, or other acquisition
|
Direct |
79,504
+19.97%
|
-
|
|
Apr 30
2025
|
Sean Ainsworth |
BUY
Grant, award, or other acquisition
|
Direct |
79,504
+32.14%
|
-
|
|
Apr 30
2025
|
Jean Bennett |
BUY
Grant, award, or other acquisition
|
Direct |
79,504
+27.13%
|
-
|
|
Apr 30
2025
|
Susan Benton |
BUY
Grant, award, or other acquisition
|
Direct |
79,504
+26.59%
|
-
|
|
Mar 24
2025
|
George Magrath Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
392,157
+22.88%
|
-
|
|
Mar 24
2025
|
Cam Gallagher |
BUY
Grant, award, or other acquisition
|
Direct |
784,314
+47.66%
|
-
|
|
Mar 13
2025
|
Rabourn Amy Zaremba SVP of Finance |
BUY
Grant, award, or other acquisition
|
Direct |
39,500
+25.74%
|
-
|
|
Mar 13
2025
|
Joseph K Schachle Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
52,500
+49.07%
|
-
|
|
Mar 13
2025
|
Bernhard Hoffmann SVP of Corp. Dev. |
BUY
Grant, award, or other acquisition
|
Direct |
29,500
+13.72%
|
-
|
|
Mar 13
2025
|
Ashwath Jayagopal Chief Scientific & Dev. Ofc. |
BUY
Grant, award, or other acquisition
|
Direct |
52,500
+29.44%
|
-
|
|
Mar 13
2025
|
Nirav S. Jhaveri Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
52,500
+21.27%
|
-
|
|
Mar 13
2025
|
George Magrath Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
330,697
+26.23%
|
-
|
|
Feb 13
2025
|
Ashwath Jayagopal Chief Scientific & Dev. Ofc. |
SELL
Payment of exercise price or tax liability
|
Direct |
5,193
-6.62%
|
$5,193
$1.15 P/Share
|
|
Feb 13
2025
|
Nirav S. Jhaveri Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,207
-5.47%
|
$8,207
$1.15 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 3.77M shares |
|---|---|
| Open market or private purchase | 210K shares |
| Conversion of derivative security | 6.93M shares |
| Payment of exercise price or tax liability | 65.4K shares |
|---|